WoundReference improves clinical decisions
 Choose the role that best describes you

What do people do for patients who have; glaucoma, diabetic retinopathy (proliferative or non), age related macular degeneration,(wet or dry), etc and those who are taking Vascular endothelial growth factor inhibitor injections. Are there absolute contraindicated conditions, should there be parallel optometrist follow ups. If someone has cataracts, do these grow faster. Can someone discuss how they deal with someone with Multiple sclerosis and past optic neuritis.
Dec 29, 2024 by Raymond Jacques,
6 replies
Elaine Horibe Song
MD, PhD, MBA
Hi Dr Jacques

Thank you for your question. Other colleagues might be able to share additional information, here are some resources. For safety of HBOT for people with ocular conditions, please refer to 'Risk of Vision Changes related to HBOT' in topic "Nursing Interventions", "Visual Acuity in HBOT", "Risks and Benefits of HBOT" and "Patient Orientation to Hyperbaric Medicine". 

For patients with ocular conditions using VEGF inhibitor and HBOT, the same safety interventions described in the links above would apply, due to the conditions for which this medication is usually indicated.

Brief background on VEGF inhibitors in ophthalmology: 
  • VEGF inhibitors, such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin), have been used in the management of ocular/retina conditions characterized by pathological neovascularization and vascular leakage. These agents have been used for wet age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), and macular edema secondary to retinal vein occlusion (RVO). By targeting VEGF, a key mediator of abnormal blood vessel growth and permeability, these therapies help stabilize and, in many cases, improve vision. [1] 
  • Anti-VEGF drugs (e.g. bevacizumab and ranibizumab) have been injected intravenously, intravitreally, and subconjunctivally to decrease vascular permeability and inhibit the formation of blood vessels. Known risks include endophthalmitis, glaucoma, vitritis, and thromboembolic events (e.g., stroke, myocardial infarction). In general, intravitreal injection offers a relative reduction of systemic side effects in exchange for ocular risks.[2] 
  • A 2022 systematic review that evaluated treatment and prophylaxis of radiation optic neuropathy concluded that early hyperbaric oxygen therapy and intravitreal anti-VEGF injections were most effective among those investigated, but require further investigation. [3] 
[1] https://www.aao.org/eye-health/drugs/anti-vegf-treatments
[2] https://journals.sagepub.com/doi/10.5301/ejo.5000670?icid=int.sj-abstract.similar-articles.1
[3] https://journals.sagepub.com/doi/10.1177/11206721221085409

Hope this helps!
Dec 30, 2024
Thank you Elaine. Can we delve deeper on this issue. I have patients coming for HBOT who have diabetic retinopathy, proliferative, age related (wet) macular degeneration, glaucoma, some on Eylea, and I wanted to know if you feel that HBOT will worsen, neutral or help their conditions. When I read articles, there is indication that HBO can help diabetic macular edema by reducing the leakage (improving the blood-retina barrier), thickness of macular (vasoconstriction effect). There is one article for helping macular degeneration (dry) but then one indicating that maybe HBO will increase the VEGF in the eye and make proliferative disorders worse. Then one article mentions that HBO might reduce VEGF in the retina, and no evidence of increasing the VEGF in the vitreous has been found. Then two articles of the retina micro hemorrhages happening with HBO.
Not sure about glaucoma as HBO might increase the pressure in the anterior chamber but reduce it in the vitreous. Then the positive effect of increase oxygen transmission across the retina but the oxygen radicals could damage the retina. And should people undergoing HBO take oral anti oxidants.
Dec 30, 2024
Mike White
MD, UHM, MMM, CWS

Dr. Jacques,


You raise some very interesting questions. The answers to those questions are not entirely clear cut. I would second Elaine's answer to your original question and will try to add my perspective as well.

With respect to cataracts, I would point you to the UHMS Indications Manual 15th ed. Pages 365 and 366 discuss ocular complication including myopia, cataracts, and retinopathy of prematurity. In essence, at the number of treatment typically used in clinical hyperbaric medicine, new cataracts should not form. It is possible for pre-existing cataracts to worsen, and patients should be told about this possible HBO side effect.

With respect to Glaucoma, multiple studies from the diving literature and HBO literature indicate that intraocular pressure is reduced with increased ambient pressure (HBO chamber or diving). A meta-analysis from 2024 (https://doi.org/10.3389/fmed.2024.1365259) agrees with this.

With respect to macular degeneration and those on anti-VEGF meds, an very interesting Ukranian study from 2022 (https://doi.org/10.3389/fmed.2024.1365259) compared outcomes in patients with diabetic macular edema who were treated with Eylea or Eylea and adjunctive HBO.  The group treated with Eylea and adjunctive HBO showed greater improvements in in visual acuity and and more profound decrease in retinal thickness than the group treated with Eylea alone.

Finally, with respect to taking prophylactic anti-oxidants with HBO. Some HBO practioners will give patients Vitamin E as a anti-oxidative measure. Some people believe this MAY help decrease the risk of oxygen toxicity seizures. One expert opinion review (https://www.sciencedirect.com/science/article/pii/S188842961730050X) indicated that anti-oxidants should be considered in at risk patients. 

I have also included a wonderful review article from 2024 that address many of the points you raise (https://www.mdpi.com/2077-0383/13/1/29). I hope this helps to answer some of your questions.


Mike White 

Dec 31, 2024
Thank you Mike. The article on IOP reductions answers the concerns for patients with glaucoma. The reference you gave for the Ukrainian study is the same one as for the IOP. Could you see and send it again. This one is useful for alleviating concerns for patients on VEGF. There seems to be support for HBO to treat diabetic macular edema. I am not an eye expert, and still need to review the differences between, diabetic macular edema, diabetic retinopathy, non proliferative and proliferative and age related macular degeneration, wet and dry. And separately, if they have aneurysms, hemorrhages in the retina...
I have read the last two, and found the last one very good.
I did find two articles that indicate that HBO is safe after refractive cornea surgery, RF, Lasik, small studies, patients were at least one year post surgery.
Dec 31, 2024
Mike White
MD, UHM, MMM, CWS

My apologies, here is the link to the Ukrainian study:

https://www.ozhurnal.com/sites/default/files/en2022-4-3.pdf

Dec 31, 2024
thank you again Mike. Of note, they received 10 sessions of 95%O2 at 1.4 atmospheres for 45 minutes. Do you know if the "1.4 atmospheres" is atm gauge and hence equivalent to 2.4 ATA or meant to say 1.4 ATA? Any reasons for shorter time sessions.
Dec 31, 2024
* Information provided without clinical evaluation and is not intended as a replacement for in-person consultation with a medical professional. The information provided through Curbside Consult is not a substitute for proper training, experience, and exercising of professional judgment. While every effort has been made to ensure the accuracy of the contents, neither the authors nor the Wound Reference, Inc. give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omissions in the contents of the work.
t
-->